Synopsis
Synopsis
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ancef
2. Cefamedin
3. Cefamezine
4. Cefazolin
5. Cephamezine
6. Cephazolin
7. Cephazolin Sodium
8. Cephazolin, Sodium
9. Gramaxin
10. Kefzol
11. Sodium Cephazolin
12. Sodium, Cefazolin
13. Sodium, Cephazolin
14. Totacef
1. Cefazolin Sodium Salt
2. 27164-46-1
3. Cefazoline Sodium
4. Ancef
5. Cefazil
6. Totacef
7. Kefzol
8. Sodium Cephazolin
9. Cefamedin
10. Gramaxin
11. Zolicef
12. Sodium Cefazolin
13. Cefacidal
14. Cephazolin Sodium
15. Cefazolin (sodium)
16. Monosodium Cefazolin
17. Sk&f 41558
18. Cefazolin Injection
19. Cefazolin And Dextrose
20. Cefazina
21. Firmacef
22. Liviclina
23. Atirin
24. Acef
25. Chebi:3483
26. Mls000028706
27. Nsc-291561
28. P380m0454z
29. Biazolina
30. Smr000058708
31. Skf 41558
32. Sk&f-41558
33. Sodium Cez
34. Cefazolin Sodium 100 Microg/ml In Acetonitrile/water
35. Ancef In Plastic Container
36. Cefabiozim
37. Cefalomicina
38. Lampocef
39. Neofazol
40. Zolisint
41. Recef
42. Zolin
43. Bor-cefazol
44. Cez Sodium
45. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1h-tetrazol-1-yl)acetyl)amino)-, Monosodium Salt (6r-trans)-
46. Monosodium (6r,7r)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1h-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
47. Lilly 46083
48. Unii-p380m0454z
49. Cefazolin Sodium [usan:usp:jan]
50. Sodium;(6r,7r)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
51. Prestwick_975
52. Einecs 248-278-4
53. Monosodium Cephazolin
54. Mfcd00056883
55. Ancef (tn)
56. Nsc 291561
57. Opera_id_1323
58. Ancef In Dextrose 5% In Plastic Container
59. Schembl40735
60. Spectrum1500164
61. Cefazolin Sodium [jan]
62. Cefazolin Sodium (jp17/usp)
63. Sodium Cez; Skf-41558
64. Cefazolin Sodium [usan]
65. Cefazolin Sodium [vandf]
66. Chembl1200523
67. Hms500a16
68. Ancef In Sodium Chloride 0.9% In Plastic Container
69. Cefazolin Sodium [mart.]
70. Cefazolin Sodium [who-dd]
71. Dtxsid901015786
72. Hms1570c14
73. Hms1920k07
74. Hms2091a10
75. Hms2097c14
76. Hms2230i22
77. Hms3260h10
78. Hms3714c14
79. Cefazolin Sodium Salt [mi]
80. Hy-b1078
81. Tox21_500274
82. Bdbm50247885
83. Ccg-40011
84. S4595
85. Akos015895533
86. Cefazolin Sodium [orange Book]
87. Cefazolin Sodium [ep Monograph]
88. Cs-4634
89. Lp00274
90. Cefazolin Sodium [usp Monograph]
91. Cefazolin Sodium Salt, 89.1-110.1%
92. Ncgc00093731-01
93. Ncgc00260959-01
94. 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-7-(2-(1h-tetrazol-1-yl)acetamido)-3-cephem-4-carboxylate
95. Ac-13166
96. Ac-31729
97. As-12230
98. Sodium (6r,7r)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1h-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
99. Eu-0100274
100. C 5020
101. C-2465
102. C08098
103. D00905
104. Q27106104
105. Cefazolin Sodium Salt, Antibiotic For Culture Media Use Only
106. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1h-tetrazol-1-yl)acetyl)amino)-, (6r-trans)-, Sodium Salt
107. 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1h-tetrazol-1-yl)acetyl]amino]-, Sodium Salt, (6r,7r)- (1:1)
108. 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1h-tetrazol-1-yl)acetyl]amino]-,(6r,7r)-,sodium
109. Sodium (6r,7r)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1h-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
110. Sodium (6r,7r)-7-(2-(1h-tetrazol-1-yl)acetamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
111. Sodium (6r,7r)-7-(2-(1h-tetrazol-1-yl)acetamido)-3-((5-methyl-1,3,4-thiadiazol-2-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
112. Sodium (6r-trans)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(1h-tetrazol-1-ylacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
113. Sodium 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1h-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylate
114. Sodium 7beta-(1h-tetrazol-1-yl)acetamido-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate
115. Sodium 7beta-[2-(1h-tetrazol-1-yl)-acetamido]-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate
116. Sodium 7beta-[2-(1h-tetrazol-1-yl)acetamido]-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate
| Molecular Weight | 476.5 g/mol |
|---|---|
| Molecular Formula | C14H13N8NaO4S3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 476.01195873 g/mol |
| Monoisotopic Mass | 476.01195873 g/mol |
| Topological Polar Surface Area | 238 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 746 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 8 | |
|---|---|
| Drug Name | Ancef in plastic container |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20mg base/ml; eq 10mg base/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 2 of 8 | |
|---|---|
| Drug Name | Cefazolin and dextrose |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | B Braun |
| 3 of 8 | |
|---|---|
| Drug Name | Cefazolin sodium |
| Drug Label | CEFAZOLIN FOR INJECTION is a semi-synthetic cephalosporin for parenteral administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxy... |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20gm base/vial; eq 100gm base/vial; eq 500mg base/vial; eq 10gm base/vial; eq 300gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Acs Dobfar; Hospira; Steri Pharma; Hikma Farmaceutica; Samson Medcl; Sandoz |
| 4 of 8 | |
|---|---|
| Drug Name | Kefzol |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 10gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Acs Dobfar |
| 5 of 8 | |
|---|---|
| Drug Name | Ancef in plastic container |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20mg base/ml; eq 10mg base/ml |
| Market Status | Prescription |
| Company | Baxter Hlthcare |
| 6 of 8 | |
|---|---|
| Drug Name | Cefazolin and dextrose |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 2gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | B Braun |
| 7 of 8 | |
|---|---|
| Drug Name | Cefazolin sodium |
| Drug Label | CEFAZOLIN FOR INJECTION is a semi-synthetic cephalosporin for parenteral administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxy... |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 20gm base/vial; eq 100gm base/vial; eq 500mg base/vial; eq 10gm base/vial; eq 300gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Acs Dobfar; Hospira; Steri Pharma; Hikma Farmaceutica; Samson Medcl; Sandoz |
| 8 of 8 | |
|---|---|
| Drug Name | Kefzol |
| Active Ingredient | Cefazolin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 10gm base/vial; eq 1gm base/vial |
| Market Status | Prescription |
| Company | Acs Dobfar |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;INTRAVENOUS - EQ 1GM BASE/5...DOSAGE - SOLUTION;INTRAVENOUS - EQ 1GM BASE/50ML (EQ 20MG BASE/ML)
USFDA APPLICATION NUMBER - 207131
DOSAGE - SOLUTION;INTRAVENOUS - EQ 2GM BASE/1...DOSAGE - SOLUTION;INTRAVENOUS - EQ 2GM BASE/100ML (EQ 20MG BASE/ML)
USFDA APPLICATION NUMBER - 207131
DOSAGE - SOLUTION;INTRAVENOUS - EQ 3GM BASE/1...DOSAGE - SOLUTION;INTRAVENOUS - EQ 3GM BASE/150ML (EQ 20MG BASE/ML)
USFDA APPLICATION NUMBER - 207131
DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 1GM BASE/VIAL
USFDA APPLICATION NUMBER - 50779
DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 2GM BASE/VIAL
USFDA APPLICATION NUMBER - 50779
DOSAGE - INJECTABLE;INJECTION - EQ 3GM BASE/V...DOSAGE - INJECTABLE;INJECTION - EQ 3GM BASE/VIAL
USFDA APPLICATION NUMBER - 50779
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Parenteral
Fillers, Diluents & Binders
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
95
PharmaCompass offers a list of Cefazolin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefazolin Sodium manufacturer or Cefazolin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefazolin Sodium manufacturer or Cefazolin Sodium supplier.
PharmaCompass also assists you with knowing the Cefazolin Sodium API Price utilized in the formulation of products. Cefazolin Sodium API Price is not always fixed or binding as the Cefazolin Sodium Price is obtained through a variety of data sources. The Cefazolin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cefazolin Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefazolin Sodium, including repackagers and relabelers. The FDA regulates Cefazolin Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefazolin Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefazolin Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cefazolin Sodium supplier is an individual or a company that provides Cefazolin Sodium active pharmaceutical ingredient (API) or Cefazolin Sodium finished formulations upon request. The Cefazolin Sodium suppliers may include Cefazolin Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Cefazolin Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cefazolin Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefazolin Sodium active pharmaceutical ingredient (API) in detail. Different forms of Cefazolin Sodium DMFs exist exist since differing nations have different regulations, such as Cefazolin Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefazolin Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Cefazolin Sodium USDMF includes data on Cefazolin Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefazolin Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefazolin Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cefazolin Sodium Drug Master File in Japan (Cefazolin Sodium JDMF) empowers Cefazolin Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cefazolin Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Cefazolin Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cefazolin Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefazolin Sodium Drug Master File in Korea (Cefazolin Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefazolin Sodium. The MFDS reviews the Cefazolin Sodium KDMF as part of the drug registration process and uses the information provided in the Cefazolin Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefazolin Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefazolin Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefazolin Sodium suppliers with KDMF on PharmaCompass.
A Cefazolin Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Cefazolin Sodium Certificate of Suitability (COS). The purpose of a Cefazolin Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefazolin Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefazolin Sodium to their clients by showing that a Cefazolin Sodium CEP has been issued for it. The manufacturer submits a Cefazolin Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefazolin Sodium CEP holder for the record. Additionally, the data presented in the Cefazolin Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefazolin Sodium DMF.
A Cefazolin Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefazolin Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefazolin Sodium suppliers with CEP (COS) on PharmaCompass.
A Cefazolin Sodium written confirmation (Cefazolin Sodium WC) is an official document issued by a regulatory agency to a Cefazolin Sodium manufacturer, verifying that the manufacturing facility of a Cefazolin Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefazolin Sodium APIs or Cefazolin Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefazolin Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Cefazolin Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefazolin Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cefazolin Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cefazolin Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cefazolin Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefazolin Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cefazolin Sodium suppliers with NDC on PharmaCompass.
Cefazolin Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefazolin Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefazolin Sodium GMP manufacturer or Cefazolin Sodium GMP API supplier for your needs.
A Cefazolin Sodium CoA (Certificate of Analysis) is a formal document that attests to Cefazolin Sodium's compliance with Cefazolin Sodium specifications and serves as a tool for batch-level quality control.
Cefazolin Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Cefazolin Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefazolin Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefazolin Sodium EP), Cefazolin Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefazolin Sodium USP).
